http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 11 Jun 2025 08:36:06 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/TC+Biopharm+%28TCBP%29+announces+complete+response+in+MRD+patient+treated+with+TCB008/24923568.html <p><i>TC</i> BioPharm<i> (Holdings) </i>PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008.</p><p>The response was achieved after the patient's second dose of 250,000,000 gamma delta t-cells, two weeks after treatment began, in total the patient received approximately 500,000,000 gamma delta t-cells over two weeks. The patient received 2 of a possible 4 infusions of TCB008 and continues to be monitored under the http://www.streetinsider.com/Corporate+News/TC+Biopharm+%28TCBP%29+announces+complete+response+in+MRD+patient+treated+with+TCB008/24923568.html Wed, 11 Jun 2025 08:36:06 -0400 TCBP http://www.streetinsider.com/Press+Releases/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html <div class="xn-content"> <ul type="disc"><li><i>First patient in Cohort B achieved CR after 2^nd dose of TCB008</i></li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>June 11, 2025</chron></span> /PRNewswire/ -- <i>TC</i> BioPharm<i> (Holdings) </i>PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html Wed, 11 Jun 2025 08:30:00 -0400 A.13873585 A.36331922 O.15851790 TCBP http://www.streetinsider.com/Press+Releases/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html <div class="xn-content"> <ul type="disc"><li><i>First patient in Cohort B achieved CR after 2^nd dose of TCB008</i></li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>June 11, 2025</chron></span> /PRNewswire/ -- <i>TC</i> BioPharm<i> (Holdings) </i>PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html Wed, 11 Jun 2025 08:30:00 -0400 A.13873585 A.36331922 O.15851790 TCBP http://www.streetinsider.com/Press+Releases/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html <div class="xn-content"> <ul type="disc"><li><i>First patient in Cohort B achieved CR after 2^nd dose of TCB008</i></li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>June 11, 2025</chron></span> /PRNewswire/ -- <i>TC</i> BioPharm<i> (Holdings) </i>PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html Wed, 11 Jun 2025 08:30:00 -0400 A.13873585 A.36331922 O.15851790 TCBP http://www.streetinsider.com/Press+Releases/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html <div class="xn-content"> <ul type="disc"><li><i>First patient in Cohort B achieved CR after 2^nd dose of TCB008</i></li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>June 11, 2025</chron></span> /PRNewswire/ -- <i>TC</i> BioPharm<i> (Holdings) </i>PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html Wed, 11 Jun 2025 08:30:00 -0400 A.13873585 A.36331922 O.15851790 TCBP http://www.streetinsider.com/PRNewswire/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html <div class="xn-content"> <ul type="disc"><li><i>First patient in Cohort B achieved CR after 2^nd dose of TCB008</i></li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>June 11, 2025</chron></span> /PRNewswire/ -- <i>TC</i> BioPharm<i> (Holdings) </i>PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html Wed, 11 Jun 2025 08:30:00 -0400 A.13873585 A.36331922 O.15851790 TCBP http://www.streetinsider.com/PRNewswire/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html <div class="xn-content"> <ul type="disc"><li><i>First patient in Cohort B achieved CR after 2^nd dose of TCB008</i></li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>June 11, 2025</chron></span> /PRNewswire/ -- <i>TC</i> BioPharm<i> (Holdings) </i>PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html Wed, 11 Jun 2025 08:30:00 -0400 A.13873585 A.36331922 O.15851790 TCBP http://www.streetinsider.com/PRNewswire/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html <div class="xn-content"> <ul type="disc"><li><i>First patient in Cohort B achieved CR after 2^nd dose of TCB008</i></li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>June 11, 2025</chron></span> /PRNewswire/ -- <i>TC</i> BioPharm<i> (Holdings) </i>PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html Wed, 11 Jun 2025 08:30:00 -0400 A.13873585 A.36331922 O.15851790 TCBP http://www.streetinsider.com/PRNewswire/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html <div class="xn-content"> <ul type="disc"><li><i>First patient in Cohort B achieved CR after 2^nd dose of TCB008</i></li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>June 11, 2025</chron></span> /PRNewswire/ -- <i>TC</i> BioPharm<i> (Holdings) </i>PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/TC+BioPharm+Announces+Complete+Response+in+Minimal+Residual+Disease+%28MRD%29+Patient/24923490.html Wed, 11 Jun 2025 08:30:00 -0400 A.13873585 A.36331922 O.15851790 TCBP http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++TC+BioPharm+%28Holdings%29++++For%3A+Mar+21/24532932.html si-local-file:///var/storage/secattach/20250321/24532932.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++TC+BioPharm+%28Holdings%29++++For%3A+Mar+21/24532932.html Fri, 21 Mar 2025 11:22:00 -0400 O.52683874 TCBP http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++TC+BioPharm+%28Holdings%29++++For%3A+Mar+21/24532932.html si-local-file:///var/storage/secattach/20250321/24532932.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++TC+BioPharm+%28Holdings%29++++For%3A+Mar+21/24532932.html Fri, 21 Mar 2025 11:22:00 -0400 O.52683874 TCBP http://www.streetinsider.com/Corporate+News/TC+Biopharm+%28TCBP%29+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532703.html <p><span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org">TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org">TC BioPharm</span>" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on <chron>March 20, 2025</chron>, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of <money>$1.00</money> per share. Management is currently working on an appeal with Nasdaq.</p><p> </p><p>The Company's http://www.streetinsider.com/Corporate+News/TC+Biopharm+%28TCBP%29+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532703.html Fri, 21 Mar 2025 10:47:54 -0400 TCBP http://www.streetinsider.com/Press+Releases/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 21, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on <chron>March 20, 2025</chron>, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of <money>$1.00</money> per http://www.streetinsider.com/Press+Releases/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html Fri, 21 Mar 2025 10:45:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/Press+Releases/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 21, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on <chron>March 20, 2025</chron>, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of <money>$1.00</money> per http://www.streetinsider.com/Press+Releases/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html Fri, 21 Mar 2025 10:45:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/Press+Releases/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 21, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on <chron>March 20, 2025</chron>, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of <money>$1.00</money> per http://www.streetinsider.com/Press+Releases/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html Fri, 21 Mar 2025 10:45:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/Press+Releases/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 21, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on <chron>March 20, 2025</chron>, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of <money>$1.00</money> per http://www.streetinsider.com/Press+Releases/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html Fri, 21 Mar 2025 10:45:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/PRNewswire/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 21, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on <chron>March 20, 2025</chron>, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of <money>$1.00</money> per http://www.streetinsider.com/PRNewswire/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html Fri, 21 Mar 2025 10:45:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/PRNewswire/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 21, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on <chron>March 20, 2025</chron>, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of <money>$1.00</money> per http://www.streetinsider.com/PRNewswire/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html Fri, 21 Mar 2025 10:45:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/PRNewswire/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 21, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on <chron>March 20, 2025</chron>, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of <money>$1.00</money> per http://www.streetinsider.com/PRNewswire/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html Fri, 21 Mar 2025 10:45:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/PRNewswire/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 21, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on <chron>March 20, 2025</chron>, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of <money>$1.00</money> per http://www.streetinsider.com/PRNewswire/TCBP+Announces+Transition+from+Nasdaq+to+OTC+Markets/24532690.html Fri, 21 Mar 2025 10:45:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/Corporate+News/TC+Biopharm+%28TCBP%29+Announces+Outsourcing+Initiatives%2C+Reducing+Burn+Rate+and+Overhead/24513357.html <p><span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org">TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org">TC BioPharm</span>" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more <span>decentralized</span> model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. </p><p>The initiatives focus on moving to a CDMO model for production to accommodate larger production demand for future clinical trials, allowing TCB to review alternatives for new manufacturing facilities incorporating newly developed automated and http://www.streetinsider.com/Corporate+News/TC+Biopharm+%28TCBP%29+Announces+Outsourcing+Initiatives%2C+Reducing+Burn+Rate+and+Overhead/24513357.html Tue, 18 Mar 2025 08:04:45 -0400 TCBP http://www.streetinsider.com/Press+Releases/TCBP+Announces+Outsourcing+Initiatives%2C+Reducing+Burn+Rate+and+Overhead/24513339.html <div class="xn-content"> <ul type="disc"><li>The company is expected to reduce core operational burn by 55% when compared to 2024</li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more <span>decentralized</span> model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. </p> <div http://www.streetinsider.com/Press+Releases/TCBP+Announces+Outsourcing+Initiatives%2C+Reducing+Burn+Rate+and+Overhead/24513339.html Tue, 18 Mar 2025 08:03:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/Press+Releases/TCBP+Announces+Outsourcing+Initiatives%2C+Reducing+Burn+Rate+and+Overhead/24513339.html <div class="xn-content"> <ul type="disc"><li>The company is expected to reduce core operational burn by 55% when compared to 2024</li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more <span>decentralized</span> model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. </p> <div http://www.streetinsider.com/Press+Releases/TCBP+Announces+Outsourcing+Initiatives%2C+Reducing+Burn+Rate+and+Overhead/24513339.html Tue, 18 Mar 2025 08:03:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/Press+Releases/TCBP+Announces+Outsourcing+Initiatives%2C+Reducing+Burn+Rate+and+Overhead/24513339.html <div class="xn-content"> <ul type="disc"><li>The company is expected to reduce core operational burn by 55% when compared to 2024</li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more <span>decentralized</span> model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. </p> <div http://www.streetinsider.com/Press+Releases/TCBP+Announces+Outsourcing+Initiatives%2C+Reducing+Burn+Rate+and+Overhead/24513339.html Tue, 18 Mar 2025 08:03:00 -0400 A.50213550 O.35229939 O.52683874 TCBP http://www.streetinsider.com/Press+Releases/TCBP+Announces+Outsourcing+Initiatives%2C+Reducing+Burn+Rate+and+Overhead/24513339.html <div class="xn-content"> <ul type="disc"><li>The company is expected to reduce core operational burn by 55% when compared to 2024</li></ul><p><span class="legendSpanClass"><location value="LU/gb.sco.edinbh" idsrc="xmltag.org" >EDINBURGH, Scotland</location></span>, <span class="legendSpanClass"><chron>March 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm (Holdings) PLC</span> ("<span value="NASDAQ-NMS:TCBP" idsrc="xmltag.org" >TC BioPharm</span>" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more <span>decentralized</span> model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. </p> <div http://www.streetinsider.com/Press+Releases/TCBP+Announces+Outsourcing+Initiatives%2C+Reducing+Burn+Rate+and+Overhead/24513339.html Tue, 18 Mar 2025 08:03:00 -0400 A.50213550 O.35229939 O.52683874 TCBP